WebMay 2, 2024 · BOULDER, Colo.--(BUSINESS WIRE)-- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that it has entered into an agreement for up to $175 million in non-dilutive clinical trial financing with certain affiliates of TPG Sixth Street Partners to reimburse Clovis’ costs and expenses related to the ATHENA clinical trial. ... The Clovis-sponsored ... WebAnalysts Holding As Pfizer Waits On Two Phase 3 Studies MarketBeat - Fri Feb 24, 8:05AM CST . Pfizer has two products with great potential, waiting on phase-3 study results. ...
Clovis (CLVS) Q1 Loss Wider than Expected, Revenues Miss
WebFeb 3, 2024 · With a strong focus on difficult-to-treat diseases and immunization, our R&D pipeline includes 84 clinical-stage projects, 28 of which are in phase 3 or have been submitted to regulatory authorities for approval. Some of these are new molecular entities while others are existing products with potential new indications, or different formulations. http://www.kuyibu.com/c_zxdxiaowei/p1672791.html refrigerator cleaning cartoon images
Buying Beaten Down Clovis Oncology Stock Ahead Of 2024 Catalysts
WebJun 14, 2024 · Talk of a takeover comes after Clovis announced positive results last week from two Phase 3 clinical trials involving medications used to treat metastatic ovarian cancer and prostate cancer. The ... WebFeb 23, 2024 · Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended December 31, 2024, and provided an update on the Company’s clinic ... WebOct 3, 2024 · CLVS Clovis Oncology Inc TRITON3 Phase 3 Trial of Rubraca® (rucaparib) Achieves Primary Endpoint in Men with Metastatic Castration-Resistant Prostate Cancer with BRCA or ATM Mutations TRITON3 study evaluating Rubraca monotherapy versus chemotherapy or second-line androgen deprivation therapy in patients with metastatic … refrigerator class 11